|
|
|
|
|
Mecamylamine
drug data and news
Mecamylamine drug data, resources, and news articles (when available). Onconews.org provides news on cancer research. This section, which includes profiles on medicines that may or not be cancer-related is in beta form. If things run smoothly we will be releasing a new format late in the summer of 2006.
|
| Generic name | Mecamylamine | ||
| Brand Names/Synonyms | Versamine; Inversine; Revertina; Inversine hydrochloride; Mecamilamina; Mecamine; Mecamine hydrochloride; Mecamylamine Hydrochloride; Mekamin hydrochloride; Mekamine; Mevasin hydrochloride; Mevasine; 2-Methylamino-2,3,3-trimethylnorbornane; 2-Methylaminoisocamphane; 2-Norbornanamine, N,2,3,3-tetramethyl-; 2-Norbornanamine, N,2,3,3-tetramethyl-, hydrochloride; 3-Methylaminoisocamphane; 3-Methylaminoisocamphane hydrochloride | ||
| Indication | For the treatment of moderately severe to severe essential hypertension and in uncomplicated cases of malignant hypertension | ||
| Sponsored links | Description | Not Available | |
| Pharmacology | Mecamylamine is a potent, oral antihypertensive agent and ganglion blocker, and is a secondary amine. Mecamylamine is indicated for the management of moderately severe to severe essential hypertension and in uncomplicated cases of malignant hypertension. Mecamylamine reduces blood pressure in both normotensive and hypertensive individuals. A small oral dosage often produces a smooth and predictable reduction of blood pressure. Although this antihypertensive effect is predominantly orthostatic, the supine blood pressure is also significantly reduced. Mecamylamine crosses the blood-brain and placental barriers. | ||
| Mechanism Of Action | Mecamylamine is a ganglionic blocker which prevents stimulation of postsynaptic receptors by acetylcholine released from presynaptic nerve endings. The hypotensive effect of Mecamylamine is attributed to reduction in sympathetic tone, vasodilation, and reduced cardiac output, and is primarily postural. | ||
| Mecamylamine News (When available) |
BioWorld Online (subscription), Targacept has one marketed product, Inversine (mecamylamine hydrochloride), which was acquired from Sunnyvale, Calif.-based Layton Bioscience Inc. ... Targacept and AstraZeneca Announce Global License and Research ... Dec 29, 2005 dBusinessNews Triad (press release), Targacept has a marketed product, Inversine(R) (mecamylamine hydrochloride), product candidates in clinical development for cognitive impairment, including ... | ||
| Dosage Forms | Tablets | ||
| Drug_Category | Antihypertensive Agents; Nicotinic Receptor Antagonist ATC:C02BB01 | ||
| Absorption | Mecamylamine is almost completely absorbed from the gastrointestinal tract | ||
| Interactions | Interactions for Mecamylamine: Patients receiving antibiotics and sulfonamides generally should not be treated with ganglion blockers. The action of Mecamylamine may be potentiated by anesthesia, other antihypertensive drugs and alcohol. | ||
| Toxicity | Not Available | ||
| Organisms Affected | Humans and other mammals | ||
| Chemical IUPAC Name | N,2,3,3-tetramethylnorbornan-2-amine | ||
| Chemical Formula | C11H21N | ||
| Molecular Weight | 167.291 g/mol | ||
| Smiles String | CC1(C2CCC(C2)C1(C)NC)C | ||
| Melting Point | <25 °C | ||
| Water Solubility | Not Available | ||
| State | Oily liquid | ||
| LogP/Hphobicity | 2.477 | ||
| Isoelectric Point | Not Available | ||
| Biotransformation | Not Available | ||
| Half Life | Not Available | ||
| Protein Binding [%] | 40% | ||
| RxList Link | RXlist | ||
| Sponsored links | |||
| Drug Reference |
http://www.drugs.com/cons/Mecamylamine.html http://www.rxlist.com/cgi/generic2/mecamylamine.htm | ||
| Drug Type | Approved Drug | ||
| Accession No | APRD00458 | ||
| CAS Registry Number | 60-40-2 | ||
| KEGG Compound ID | C07511 | ||
| PubChem ID | SID:9714 | ||
| PharmGKB ID | PA450334 | ||
| SwissProt ID | Not Available | ||
| GenBank ID | Not Available | ||
| Drug ID Number [DIN] | Not Available |
|
Home | About | Cancers | Treatment | Medications Copyright onconews.org 2005. All Rights Reserved. |